Related Experiment Videos
New indium-111 labeled biotin derivatives for improved immunotargeting
F Virzi1, B Fritz, M Rusckowski
1Department of Nuclear Medicine, University of Massachusetts Medical Center, Worcester 01655.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology
|January 1, 1991
Summary
Modifying biotin molecules significantly reduced off-target accumulation in normal tissues and tumors for radioimmunotargeting. Biotinyl-hydrazino-EDTA (EDTA-B1) showed superior target-to-nontarget ratios compared to commercial derivatives.
Area of Science:
- Biomedical imaging
- Radiopharmaceutical chemistry
- Molecular targeting
Background:
- Streptavidin-conjugated antibodies and labeled biotin improve radioimmunotargeting by reducing background.
- However, nonspecific accumulation of 111In-biotin in normal tissues and tumors remains a challenge.
- Investigating modified biotin molecules is crucial to enhance targeting specificity.
Purpose of the Study:
- To synthesize and evaluate novel EDTA and DTPA derivatives of biotin.
- To reduce nonspecific uptake in normal tissues and tumors without compromising specific localization.
- To compare the biodistribution and targeting efficiency of modified biotin chelates.
Main Methods:
- Synthesis of three EDTA and DTPA biotin derivatives.
- Investigation of a commercial biotin derivative (DTPA-B2).
- Administration of labeled biotin chelates to mice with avidin beads and in vitro tumor cell lines.
Main Results:
- Significant variations in biodistribution were observed among biotin derivatives.
- Biotinyl-hydrazino-EDTA (EDTA-B1) exhibited the lowest normal tissue accumulation and equivalent target uptake.
- EDTA-B1 achieved a target-to-nontarget ratio of 140:9 compared to DTPA-B2 at 24 hours.
- EDTA-B1 showed 3-5 fold lower accumulation in tumor cells independent of streptavidin.
Conclusions:
- Modification of biotin species can effectively alter biodistribution.
- Novel biotin derivatives can reduce both normal tissue and tumor accumulation.
- EDTA-B1 represents a promising candidate for improved radioimmunotargeting strategies.